Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 20, 2023, serves as a transaction notification for the month of October 2023. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction data:
- Transaction Date: October 17, 2023
- Dividend Payment Date: October 12, 2023
- Ordinary Shares Price: £15.0571 per share (London Stock Exchange)
- American Depositary Shares (ADS) Price: $36.6136 per share (New York Stock Exchange)
- Transaction Nature: Acquisition of shares via dividend reinvestment.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly records routine compliance disclosures regarding insider shareholdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific transactions.
Important Facts for Investor Verification
- Multiple senior executives, including CEO Emma Walmsley and Chief Scientific Officer Tony Wood, acquired shares solely through dividend reinvestment.
- Transactions occurred on both the London Stock Exchange (Ordinary Shares) and the New York Stock Exchange (ADSs).
- The filing confirms the company paid dividends on October 12, 2023, which were reinvested on October 17, 2023.
- Share prices at the time of reinvestment were £15.0571 for Ordinary Shares and $36.6136 for ADSs.